winfuran Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
  • InChIKey: XGZZHZMWIXFATA-UEZBDDGYSA-N
  • Mol. Mass: 476.57
  • ALogP: 3.09
  • ChEMBL Molecules:
    nalfurafine  
    nalfurafine hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-(n-methyl-trans-3-(3-furyl)acrylamido)morphinan hydrochloride | nalfurafine | nalfurafine hcl | nalfurafine hydrochloride | remitch | trk 820 | trk-820 | winfuran

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Kidney Failure, Chronic (Phase 1)

Pruritus (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue